Why the study?
Target LDL-C levels are rarely achieved in routine clinical practice, largely due to infrequent prescribing of high-dose statins.
Does intensive statin therapy reduce cardiovascular complications compared to initial doses in patients with high cardiovascular risk?
Does intensive statin therapy reduce cardiovascular complications compared to initial doses in patients with high cardiovascular risk?
Intensive statin therapy is safe, well-tolerated, and provides an additional 16% reduction in cardiovascular complications, highlighting the need to increase statin doses in routine clinical practice.
Answers are grounded in this paper and cite their sources.
May support higher statin doses for added CV risk reduction; hypothesis-generating and should not yet change practice.
HMG-CoA reductase inhibitors (statins) were discovered in the early 1970s in Japan and were originally used to treat patients with hereditary hyperlipidemia. In the late 1990s and early 2000s, clinical trials using statins for primary and secondary prevention showed the possibility of reducing cardiovascular (CV) and, in some cases, all-cause mortality. Intensive statin therapy (atorvastatin 80 mg/day and rosuvastatin 40 mg/day) compared to initial doses provides an additional 16% reduction in CV complications. Regression studies with the original rosuvastatin using intracoronary ultrasound and other modern methods have shown the possibility of stabilization and regression of atherosclerosis in the carotid and coronary arteries. High-dose statin therapy is generally well tolerated; the incidence of clinically significant adverse liver reactions does not exceed 2-3 per 100,000 people, and the incidence of myopathies with increased creatine kinase over 10 upper limits of normal is not higher than 1 per 10,000 people per year. Long-term statin treatment does not increase the risk of dementia and, in some studies, reduced the risk of Alzheimer's disease. Achieving target levels of low-density lipoprotein cholesterol (LDL-C) in routine practice does not exceed 5-11%; one of the main reasons for that is the rare (2-3%) prescription of high doses of statins. Increasing statin doses in routine clinical practice will optimize the treatment of patients with high CV risk and will contribute to further reduction of mortality in our country.
No takes yet. Share an insight, caveat, or question.
Andrey V. Susekov (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: